CVS HEALTH CORPORATION (CVS) FY2026 Q1 Balance Sheet

CVS HEALTH CORPORATION (CVS) FY2026 Q1 Balance Sheet

Balance sheet as of 2026-03-31. The chart shows assets, liabilities and equity at that date.

Assets

252,974,000,000 US dollars

Current assets

74,817,000,000 US dollars

Non-current assets

178,157,000,000 US dollars

Liabilities

175,337,000,000 US dollars

Current liabilities

86,406,000,000 US dollars

Non-current liabilities

88,931,000,000 US dollars

Equity

77,637,000,000 US dollars

Noncontrolling interest

181,000,000 US dollars. Included in consolidated equity; this amount is not added again.

Accounts receivable, net

40,992,000,000 US dollars

Inventories

17,770,000,000 US dollars

Cash and cash equivalents

9,542,000,000 US dollars

Other current assets

4,253,000,000 US dollars

Investments

2,260,000,000 US dollars

Goodwill

85,478,000,000 US dollars

Long-term investments

32,407,000,000 US dollars

Intangible assets, net

25,070,000,000 US dollars

Operating lease right-of-use assets

14,741,000,000 US dollars

Property and equipment, net

13,037,000,000 US dollars

Other assets

7,424,000,000 US dollars

Pharmacy claims and discounts payable

26,149,000,000 US dollars

Accrued expenses and other current liabilities

22,258,000,000 US dollars

Accounts payable

16,922,000,000 US dollars

Health care costs payable

15,518,000,000 US dollars

Current portion of long-term debt

2,580,000,000 US dollars

Current portion of operating lease liabilities

1,904,000,000 US dollars

Other insurance liabilities

1,075,000,000 US dollars

Long-term debt

60,531,000,000 US dollars

Long-term operating lease liabilities

13,330,000,000 US dollars

Other long-term liabilities

6,707,000,000 US dollars

Other long-term insurance liabilities

4,592,000,000 US dollars

Deferred income taxes

3,771,000,000 US dollars

Retained earnings

63,282,000,000 US dollars

Common stock, par value $0.01: 3,200 shares authorized; 1,788 shares issued and 1,273 shares outstanding as of March 31, 2026 and 1,787 shares issued and 1,271 shares outstanding as of December 31, 2025 and capital surplus

50,679,000,000 US dollars

Accumulated other comprehensive income

201,000,000 US dollars

Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding

0 US dollars

Noncontrolling interests

181,000,000 US dollars

Treasury stock, at cost: 515 and 516 shares as of March 31, 2026 and December 31, 2025

negative 36,706,000,000 US dollars

Gross equity (calculated)

114,343,000,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

• Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
• Treasury shares and other negative equity contributions reduce equity.